Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Wall Street Week Ahead: Coca-Cola, PepsiCo, CVS Health

Published 02/09/2015, 06:56 AM
Updated 05/14/2017, 06:45 AM

Wall Street has an exciting week ahead as the two biggest beverage companies, Coca Cola and PepsiCo, are set to battle it out in earnings. In addition, CVS Health is also set to announce earnings this week. What can investors expect?

Coca-Cola (NYSE: KO):

Coca-Cola (NYSE:KO) is scheduled to announce its fourth quarter and full year 2014 earnings results on Tuesday, February 10th before the market opens. The company is expected to post earnings of $0.42 a share, down from $0.46 a share the same quarter a year prior. Coca-Cola is also expected to post $10.76 billion in revenue, marking a -3% decrease on a year-over-year basis. Analysts have estimated that Coca-Cola’s full year 2015 earnings per share will be $2.02 and $45.73 billion in revenue, indicating no expectations of growth.

If Coca-Cola meets analysts’ consensus estimates in Q4, this will mark the seventh out of the past eight quarters in which the company reports a negative decrease in revenue year-over-year.

Coca-Cola rakes in the majority of its profit outside of the United States. The company warned investors in December that foreign currencies would cut its profit by 6% to 7% in Q4 due to the strengthening dollar.

Investors will be looking for an update on new drinks, such as Coca-Cola Life, the green-labeled, low-sugar soft drink which caters to consumers who are moving away from artificially-sweetened diet drinks.

Investors will also be looking for an update on the two new strategic partnerships with Keurig Green Mountain (NASDAQ:GMCR) and Monster Beverage (NASDAQ:MNST). Coca-Cola bought back a 16.7% stake in both companies in 2014. With that said, investors will be looking to see if Coca-Cola will acquire either company entirely.

On average, the top analyst consensus for Coca-Cola on TipRanks is Hold.

KO Consensus

PepsiCo (NYSE: PEP):


Coca-Cola rival PepsiCo (NYSE:PEP) is set to announce its fourth quarter and full year 2014 earnings report on Wednesday, February 11th before the market opens. The company is expected to post $1.08 earnings per share, up from $1.05 earnings per share the same quarter last year.

Investors will be looking for an update from Pepsi on its new Pepsi True, a direct competitor with Coca Cola Life and a beverage made in attempt to battle declining diet soda volumes in the domestic market.

In addition, PepsiCo recently announced a new quarterly dividend of $0.66 per share to be paid to shareholders on Tuesday, March 31st. This represents a $2.62 annualized dividend and a dividend yield of 2.71%.

On average, the top analyst consensus for PepsiCo on TipRanks is Strong Buy.

PEP Analyst Consensus

CVS Health (NYSE: CVS):

NYSE:CVS is scheduled to announce its fourth quarter 2014 earnings results on Tuesday, February 10th before the market opens. The company is expected to post $1.21 earnings per share, up from $1.12 earnings per share the same quarter a year prior. CVS is also expected to post $36.06 billion in revenue, marking a 9.8% increase on a year-over-year basis.

CVS is expected to thrive from prescription growth and its specialty drugs business due to a growing senior population and a greater number of individuals eligible for government health care benefits because of the Affordable Care Act. However, if CVS matches analysts’ consensus estimate, the company’s earnings per share growth rate would mark the third quarter in a row of a slowdown. With that said, the same quarter last year was the last full quarter that included the sale of tobacco products.

CVS is also expected to benefit from the growing specialty drug category with treatments for diseases like hepatitis and multiple sclerosis. Most recently, CVS made a deal with Gilead Sciences in which the pharmacy will exclusively distribute GILD’s Sovaldi and Harvoni in favor of competitors to treat patients with hepatitis C.

On average, the top analyst consensus for CVS on TipRanks is Moderate Buy.

CVX Analyst Consensus

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.